Acuitas Therapeutics

10 articles about Acuitas Therapeutics

• BIOVECTRA Signs Service Agreement With Acuitas Therapeutics for Unique Lipid Nanoparticle (LNP) Delivery System Used in Manufacturing mRNA-Based Therapies

  10/5/2023

  BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ best-in-class LNP technology platform for manufacturing mRNA-based therapeutics.

• Bayer Strengthens Gene Therapy Portfolio With Lipid Nanoparticle Technology From Acuitas Therapeutics

  6/6/2023

  Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle delivery systems for molecular therapeutics.

• IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System

  11/10/2022

  IMUNON, Inc.(NASDAQ: IMNN) and Acuitas Therapeutics, a private biotechnology company focused on the development of delivery systems for nucleic acid vaccines and therapeutics based on lipid nanoparticles (LNP), today announced the signing of an agreement to evaluate the combination of IMUNON’s PLACCINE nucleic acid vaccine constructs formulated with Acuitas’ proprietary lipid delivery technology.

• Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases

  8/25/2022

  Arbor Biotechnologies today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles (LNP).

• GC Biopharma Concludes Agreement With Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics

  4/28/2022

  GC Biopharma and Acuitas Therapeutics announced that they have entered into a Development and Option agreement for Acuitas’ LNP technology.

• 

  Who Should Get Credit for Saving the World from COVID-19?

  3/22/2022

  Who is to thank for the COVID vaccine? Many major biopharma companies are asking that question after a series of lawsuits over patent rights to the vaccine and its associated technology.  

• Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics

  1/10/2022

  Pfizer Inc. and Acuitas Therapeutics announced they have entered into a Development and Option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development.

• 

  Pfizer Triple-Partners for Future mRNA Vaccines and Genetic Medicines

  1/10/2022

  Around 40% of Pfizer’s portfolio was realized through partnerships, and Monday, the pharma giant announced three more collaborative deals.  

• Arbutus Biopharma Injunction Survives Attempted Appeal By Acuitas Therapeutics

  4/13/2017

• Acuitas Therapeutics Release: Findings Published In Nature Communications Show That Mrna-LNP Encoding A Neutralizing Antibody Protect Humanized Mice From HIV Challenge

  3/2/2017